The context of the psychedelic experience plays a critical role in determining positive outcomes for patients.
The answer is yes and no. It's a matter of perspective.
The similarities between aeruginascin and other serotonin analogs may connect the dots between aeruginascin and Wood Lover Paralysis
Improvements in depression and anxiety are associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning.
Bruce Tobin is asking Health Canada to approve psilocybin to treat anxiety and depression in end-of-life patients.
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.
Psilocybin-assisted therapy is showing promise for quitting smoking, but how does it work?
Pharma companies with expertise in 5-HT3 receptors are focusing on antagonist drugs to combat nausea and vomiting in chemotherapy patients.
Psilocybin produces more insightful and mystical experiences, but dextromethorphan causes greater feelings of disembodiment.
Researchers push to move psilocybin from Schedule I to Schedule IV if Phase III clinical trials are successful.